OSI Tarceva Approval Falls Flat: Wall Street Wants Aggressive Pricing
Executive Summary
OSI's early experience with the launch of Tarceva suggests that managing investor expectations for a new-model breakthrough medicine may be as challenging as demonstrating a survival benefit in lung cancer